There Is More Than One Issue With The Provision Of RSV Shots
There Is More Than One Issue With The Provision Of RSV Shots On October 13, Sanofi, a pharmaceutical company, made an unexpected announcement: supplies of Beyfortus, a new medicine called nirsevimab that is intended to shield babies from severe respiratory syncytial virus (RSV) infections, had not kept up with demand. This is the first Respiratory Syncytial Virus season the medication has been accessible, and uptake has been strong, so in some ways that’s excellent news. It makes sense: Respiratory Syncytial Virus is the leading cause of hospitalisations for infants globally. The flood of new vaccines and other medicines that have been released this autumn to help avert the worst effects of the infection has been warmly greeted by paediatricians. Furthermore, parents still trust paediatricians and pay attention to their advice about vaccines, even in spite of the brief increase in vaccine hesitancy among children during the epidemic. However, it also means that some kids haven’t been a...